Hypertension induced by chemotherapeutic and immunosuppresive agents: A new challenge

被引:30
作者
Aad, Simon Abi [1 ]
Pierce, Matthew [1 ]
Barmaimon, Guido [1 ]
Farhat, Fadi S. [2 ]
Benjo, Alexandre [1 ]
Mouhayar, Elie [3 ]
机构
[1] Mt Sinai Lukes Roosevelt Hosp Ctr, New York, NY USA
[2] Lebanese Univ, Dept Hematol Oncol, Beirut, Lebanon
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
Hypertension; Chemotherapy; Cancer; Review; BLOOD-PRESSURE; LONG-TERM; RENAL-FUNCTION; TRANSPLANT RECIPIENTS; CYCLOSPORINE; THERAPY; INHIBITOR; ERYTHROPOIETIN; TACROLIMUS; MANAGEMENT;
D O I
10.1016/j.critrevonc.2014.08.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hypertension is a common adverse effect of certain anti neoplastic therapy. The incidence and severity of hypertension are dependent mainly on the type and the dose of the drug. Methods: We reviewed the literature for studies that reported the effect of anti neoplastic agents on blood pressure in patients with malignancies. The medical databases of PubMed, MEDLINE and EMBASE were searched for articles published in English between 1955 and June 2012. The effects of specific agents on blood pressure were analyzed. Results and conclusions: Hypertension is a prevalent adverse effect of many of the new chemotherapy agents such as VEGF inhibitors. Approximately 30% of patients treated for cancer will have concomitant hypertension, and crucial chemotherapy can sometimes be stopped due to new onset or worsening severe hypertension. The importance of a timely diagnosis and optimal management of HTN in this group of patients is related to the facts that HTN is a well established risk factor for chemotherapy-induced cardiotoxicity and if left untreated, can alter cancer management and result in dose reductions or termination of anti-cancer treatments as well as life-threatening end organ damage. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 68 条
  • [1] REVERSIBLE RENAL-FAILURE DUE TO THE USE OF CAPTOPRIL IN A RENAL-ALLOGRAFT RECIPIENT TREATED WITH CYCLOSPORINE
    AHMAD, T
    COULTHARD, MG
    EASTHAM, EJ
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1989, 4 (04) : 311 - 312
  • [2] [Anonymous], 2003, HYPERTENSION PRIMER
  • [3] ACUTE CORONARY EVENTS FOLLOWING CISPLATIN-BASED CHEMOTHERAPY
    BERLINER, S
    RAHIMA, M
    SIDI, Y
    TEPLITSKY, Y
    ZOHAR, Y
    NUSSBAUM, B
    PINKHAS, J
    [J]. CANCER INVESTIGATION, 1990, 8 (06) : 583 - 586
  • [4] Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor-null mice
    Bernal-Mizrachi, C
    Weng, S
    Feng, C
    Finck, BN
    Knutsen, RH
    Leone, TC
    Coleman, TY
    Mecham, RP
    Kelly, DP
    Semenkovich, CF
    [J]. NATURE MEDICINE, 2003, 9 (08) : 1069 - 1075
  • [5] EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
    Bokemeyer, C
    Aapro, MS
    Courdi, A
    Foubert, J
    Link, H
    Österborg, A
    Repetto, L
    Soubeyran, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) : 2201 - 2216
  • [6] Insights into glucocorticoid-associated hypertension
    Brem, AS
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (01) : 1 - 10
  • [7] Brookes L., 2003, AM SOC HYP 18 ANN SC
  • [8] Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients - A randomized, double-blind study
    Bursztyn, M
    Zelig, O
    Or, R
    Nagler, A
    [J]. TRANSPLANTATION, 1997, 63 (07) : 1034 - 1036
  • [9] Calhoun DAZA, 2003, CARDIOLOGY, P463
  • [10] Chen Ye-Hui, 2009, Zhonghua Yi Xue Za Zhi, V89, P704